BioSpace News Archive

POXEL SA announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to PXL770 for the treatment of patients with autosomal-dominant polycystic kidney disease.

Lumanity announced that it has expanded its pharmaceutical product launch capabilities, creating a technology-enabled, end-to-end launch excellence service offering.

Seneca Therapeutics, Inc. announced it had received FDA clearance to begin a Phase I/II clinical study utilizing Seneca Valley Virus in combination with a checkpoint inhibitor.

AmplifyBio, a contract research organization focused on accelerating innovation across pharmaceutical modalities; announced the acquisition of select assets from PACT Pharma, Inc., a privately held biopharmaceutical company developing neoantigen-specific T cell receptor cell therapies.

CollPlant Biotechnologies today announced that the Company’s Deputy CEO & Chief Financial Officer Eran Rotem will present a company overview at the Dawson James 7th Annual Small Cap Growth Conference at the Wyndham Grand Hotel in Jupiter, Florida.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that Craig B. Thompson , M.D., has been elected to the Board of Directors, effective immediately. Dr. Thompson has also been appointed to serve on the Technology Committee of the Regeneron Board.

Theseus Pharmaceuticals, Inc. today announced that it has nominated THE-349 as the development candidate for its epidermal growth factor receptor (EGFR) inhibitor program in non-small cell lung cancer (NSCLC).

Nevro Corp. today announced that Nevro’s HFX 10 kHz Therapy is the only form of spinal cord stimulation (SCS) therapy to be referenced by the American Association of Clinical Endocrinology (AACE) in its 2022 Diabetes Clinical Practice Guideline to treat painful diabetic neuropathy (PDN).

TRITON3 Phase 3 Trial of Rubraca ® (rucaparib) Achieves Primary Endpoint in Men with Metastatic Castration-Resistant Prostate Cancer with BRCA or ATM Mutations.

Aura Biosciences Inc. today announced that interim Phase 2 data evaluating the safety and efficacy of suprachoroidal (SC) administration using its first VDC product candidate, belzupacap sarotalocan (AU‑011), for the first-line treatment of patients with early-stage choroidal melanoma (indeterminate lesions and small choroidal melanoma (IL/CM)), were presented at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting held September 30-October 3, 2022, in Chicago, IL.